X1 combines PET/CT with RefleXion's biology-guided radiotherapy, which directs treatment photons to sites of cancer detected with the PET/CT component, the company said. Treatments at UPMC should begin in the summer.
The X1 is currently approved for use in conventional stereotactic body radiotherapy, intensity-modulated radiation therapy, and stereotactic radiosurgery. The biology-guided radiotherapy feature is under investigational use until it receives official approval from the U.S. Food and Drug Administration.
In April 2020, RefleXion sold its first X1 system for installation at the Stanford Cancer Institute at Stanford University.
Copyright © 2021 AuntMinnie.com